

Clinical trials of ranolazine 1000mg

TrialResults-center www.trialresultscenter.org

1 stable angina

| Trial | Treatments | Patients | Trials design and methods |
|---|--|---|--|
| ranolazine 1000mg vs placebo | | | |
| MARIZA , 2004 n=191/191 follow-up: 1 week | ranolazine 500 mg twice daily (sustained-release ranolazine 500, 1,000, or 1,500 mg) versus placebo | Patients with angina-limited exercise | Cross over double blind US, Czech Republic, Poland, Canada |
| RAN080 , 2005 n=158/158 follow-up: 1 week | ranolazine IR 400mg TID versus placebo | patients who had symptom-limited exercise | Cross over double blind Europe, canada |
| ranolazine 1000mg vs placebo (on top standard treatment) | | | |
| CARISA 1000mg , 2004 n=261/258 follow-up: 12 weeks | ranolazine 1000mg (in combination with beta-blockers or calcium antagonists) versus placebo | patients with severe chronic angina who have symptoms of chronic angina and who experience angina and ischemia at low workloads despite taking standard doses of atenolol, amlodipine, or diltiazem | Parallel groups double blind |
| ranolazine 1000mg + amlodipine vs placebo + amlodipine | | | |
| ERICA , 2006 [NCT00091429] n=281/284 follow-up: 6 weeks | ranolazine 1000 mg twice a day for 6 weeks + amlodipine (10 mg/d) versus placebo + amlodipine (10 mg/d) | patients with stable chronic angina already treated with the maximal dose of amlodipine (10mg/d) | Parallel groups double blind Europe, USA, Canada |

More details and results :

- anti-anginal drugs for stable angina in all type of patients at <http://www.trialresultscenter.org/go-Q263>

References

MARIZA, 2004:

Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson JJ, Hebert DA, Wolff AA Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-82 [[15093870](#)]

RAN080, 2005:

Rousseau MF, Pouleur H, Cocco G, Wolff AA Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005;95:311-6 [15670536]

CARISA 1000mg, 2004:

Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004 Jan 21;291:309-16 [14734593]

ERICA, 2006:

Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006 Aug 1;48:566-75 [16875985]

2 coronary artery disease

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|--|
| ranolazine 1000mg vs placebo | | | |
| MARIZA , 2004 n=191/191 follow-up: 1 week | ranolazine 500 mg twice daily (sustained-release ranolazine 500, 1,000, or 1,500 mg) versus placebo | Patients with angina-limited exercise | Cross over double blind US, Czech Republic, Poland, Canada |
| RAN080 , 2005 n=158/158 follow-up: 1 week | ranolazine IR 400mg TID versus placebo | patients who had symptom-limited exercise | Cross over double blind Europe, canada |
| ranolazine 1000mg vs placebo (on top standard treatment) | | | |
| CARISA 1000mg , 2004 n=261/258 follow-up: 12 weeks | ranolazine 1000mg (in combination with beta-blockers or calcium antagonists) versus placebo | patients with severe chronic angina who have symptoms of chronic angina and who experience angina and ischemia at low workloads despite taking standard doses of atenolol, amlodipine, or diltiazem | Parallel groups double blind |
| ranolazine 1000mg + amlodipine vs placebo + amlodipine | | | |
| ERICA , 2006 [NCT00091429] n=281/284 follow-up: 6 weeks | ranolazine 1000 mg twice a day for 6 weeks + amlodipine (10 mg/d) versus placebo + amlodipine (10 mg/d) | patients with stable chronic angina already treated with the maximal dose of amlodipine (10mg/d) | Parallel groups double blind Europe, USA, Canada |

More details and results :

- anti-anginal drugs for coronary artery disease in all type of patients at <http://www.trialresultscenter.org/go-Q351>

References

MARIZA, 2004:

Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson JJ, Hebert DA, Wolff AA Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. *J Am Coll Cardiol* 2004;43:1375-82 [[15093870](#)]

RAN080, 2005:

Rousseau MF, Pouleur H, Cocco G, Wolff AA Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. *Am J Cardiol* 2005;95:311-6 [[15670536](#)]

CARISA 1000mg, 2004:

Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. *JAMA* 2004 Jan 21;291:309-16 [[14734593](#)]

ERICA, 2006:

Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. *J Am Coll Cardiol* 2006 Aug 1;48:566-75 [[16875985](#)]

Entry terms: ranolazine, renolazine, RS 43285-193, Ranexa, RS 43285, RS-43285,